Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Adaptive radiotherapy in head and neck cancer is required to avoid tumor underdose.

Castelli J, Simon A, Rigaud B, Chajon E, Thariat J, Benezery K, Vauleon E, Jegoux F, Henry O, Lafond C, de Crevoisier R.

Acta Oncol. 2018 Apr 28:1-4. doi: 10.1080/0284186X.2018.1468086. [Epub ahead of print] No abstract available.

PMID:
29706107
2.

Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

Gauvain C, Vauléon E, Chouaid C, Lerhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I.

Lung Cancer. 2018 Feb;116:62-66. doi: 10.1016/j.lungcan.2017.12.008. Epub 2017 Dec 14.

PMID:
29413052
3.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24.

4.

Dual IRE1 RNase functions dictate glioblastoma development.

Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares-Lupon N, Schmit K, Le Reste PJ, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E.

EMBO Mol Med. 2018 Mar;10(3). pii: e7929. doi: 10.15252/emmm.201707929.

5.

CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.

Avril T, Etcheverry A, Pineau R, Obacz J, Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, Decker PA, Sarkaria JN, Vauléon E, Chiforeanu DC, Clavreul A, Mosser J, Chevet E, Quillien V.

Clin Cancer Res. 2017 Dec 1;23(23):7360-7374. doi: 10.1158/1078-0432.CCR-17-1549. Epub 2017 Sep 22.

6.

Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers.

Avril T, Vauléon E, Chevet E.

Oncogenesis. 2017 Aug 28;6(8):e373. doi: 10.1038/oncsis.2017.72. Review.

7.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191.

8.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
9.

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).

Lebellec L, Chauffert B, Blay JY, Le Cesne A, Chevreau C, Bompas E, Bertucci F, Cupissol D, Fabbro M, Saada-Bouzid E, Duffaud F, Feuvret L, Bonneville-Levard A, Bay JO, Vauleon E, Vinceneux A, Noel G, Penel N, Mir O.

Eur J Cancer. 2017 Jul;79:119-128. doi: 10.1016/j.ejca.2017.03.037. Epub 2017 May 4.

PMID:
28478340
10.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Oncotarget. 2016 Sep 20;7(38):61916-61929. doi: 10.18632/oncotarget.11322.

11.

Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.

Castelli J, Feuvret L, Haoming QC, Biau J, Jouglar E, Berger A, Truc G, Gutierrez FL, Morandi X, Le Reste PJ, Thillays F, Loussouarn D, Nouhaud E, Crehange G, Antoni D, Vauleon E, de Crevoisier R, Noel G.

J Neurooncol. 2016 Aug;129(1):85-92. doi: 10.1007/s11060-016-2142-9. Epub 2016 May 11.

PMID:
27169763
12.

Characteristics of gliomas in patients with somatic IDH mosaicism.

Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, Cartalat-Carel S, Meyronet D, Dehais C, Honnorat J, Sanson M, Ducray F.

Acta Neuropathol Commun. 2016 Mar 31;4:31. doi: 10.1186/s40478-016-0302-y.

13.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.

Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25.

PMID:
26724422
14.

Intérêt de la surveillance scannographique après cystectomie pour cancer.

Peyronnet B, Alimi Q, Mathieu R, Laguerre B, Vauleon E, Vincendeau S, Manunta A, Guille F, Rioux-Leclercq N, Bensalah K, Verhoest G.

Prog Urol. 2014 Nov;24(13):808. doi: 10.1016/j.purol.2014.08.057. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461583
15.

Primary Leptomeningeal Gliomatosis in Children and Adults: A Morphological and Molecular Comparative Study With Literature Review.

Tauziede-Espariat A, Maues de Paula A, Pages M, Laquerriere A, Caietta E, Delpont B, Viennet G, Medeiros de Bustos E, Moulin T, Barnerias C, Vauleon E, Grill J, Chiforeanu D, Vasiljevic A, Varlet P.

Neurosurgery. 2016 Mar;78(3):343-52. doi: 10.1227/NEU.0000000000001028.

PMID:
26397750
16.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A; POLA Network.

Neurology. 2015 Oct 13;85(15):1325-31. doi: 10.1212/WNL.0000000000002014. Epub 2015 Sep 18.

17.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group.

Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14. Review.

PMID:
26371288
18.

DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.

Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, de Tayrac M, Delattre JY, Mosser J.

PLoS One. 2014 Sep 18;9(9):e104455. doi: 10.1371/journal.pone.0104455. eCollection 2014.

19.

Proteomic analysis underlines the usefulness of both primary adherent and stem-like cell lines for studying proteins involved in human glioblastoma.

Collet B, Avril T, Aubry M, Hamlat A, Le Reste PJ, Chiforeanu D, Vauleon E, Mosser J, Quillien V.

J Proteomics. 2014 Oct 14;110:7-19. doi: 10.1016/j.jprot.2014.07.022. Epub 2014 Aug 1.

PMID:
25088051
20.

Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.

Chajon E, Lafond C, Louvel G, Castelli J, Williaume D, Henry O, Jégoux F, Vauléon E, Manens JP, Le Prisé E, de Crevoisier R.

Radiat Oncol. 2013 May 30;8:132. doi: 10.1186/1748-717X-8-132.

21.

SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.

Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S, Uro-Coste E, Mokhtari K, Jouvet A, Honnorat J, Chinot O, Ramirez C, Beauchesne P, Benouaich-Amiel A, Godard J, Eimer S, Parker F, Lechapt-Zalcman E, Colin P, Loussouarn D, Faillot T, Dam-Hieu P, Elouadhani-Hamdi S, Bauchet L, Langlois O, Le Guerinel C, Fontaine D, Vauleon E, Menei P, Fotso MJ, Desenclos C, Verrelle P, Ghiringhelli F, Noel G, Labrousse F, Carpentier A, Dhermain F, Delattre JY, Figarella-Branger D; POLA Network.

PLoS One. 2012;7(10):e45950. doi: 10.1371/journal.pone.0045950. Epub 2012 Oct 10. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/27807b78-9c79-414a-a47e-fb3eca621be4. Verelle, Pierre [corrected to Verrelle, Pierre].

22.

Immune genes are associated with human glioblastoma pathology and patient survival.

Vauléon E, Tony A, Hamlat A, Etcheverry A, Chiforeanu DC, Menei P, Mosser J, Quillien V, Aubry M.

BMC Med Genomics. 2012 Sep 14;5:41. doi: 10.1186/1755-8794-5-41.

23.

[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].

Vauleon E, Mesbah H, Gedouin D, Lecouillard I, Louvel G, Hamlat A, Riffaud L, Carsin B, Quillien V, Audrain O, Lesimple T.

Bull Cancer. 2012 Feb 1;99(2):121-6. doi: 10.1684/bdc.2011.1528. French.

24.

Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.

Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V.

Brain Pathol. 2012 Mar;22(2):159-74. doi: 10.1111/j.1750-3639.2011.00515.x. Epub 2011 Sep 16.

PMID:
21790828
25.

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.

Cancer. 2012 Jan 1;118(1):147-56. doi: 10.1002/cncr.26255. Epub 2011 Jun 28.

26.

Mechanisms of immunomodulation in human glioblastoma.

Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V.

Immunotherapy. 2011 Apr;3(4 Suppl):42-4. doi: 10.2217/imt.11.39. Review.

PMID:
21524170
27.

Cementoplasty for painful bone metastases: a series of 42 cases.

Botton E, Edeline J, Rolland Y, Vauléon E, Le Roux C, Mesbah H, Porée P, Audrain O, Raoul JL.

Med Oncol. 2012 Jun;29(2):1378-83. doi: 10.1007/s12032-011-9939-3. Epub 2011 Apr 17.

PMID:
21499928
28.

[MGMT analysis in gliomas].

Quillien V, Vauléon E, Saikali S, Lesimple T, Hamlat A, Etcheverry A, Mosser J.

Bull Cancer. 2011 Mar;98(3):291-303. doi: 10.1684/bdc.2011.1332. Review. French.

29.

DNA methylation in glioblastoma: impact on gene expression and clinical outcome.

Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, Quillien V, Mosser J.

BMC Genomics. 2010 Dec 14;11:701. doi: 10.1186/1471-2164-11-701.

30.

Overview of cellular immunotherapy for patients with glioblastoma.

Vauleon E, Avril T, Collet B, Mosser J, Quillien V.

Clin Dev Immunol. 2010;2010. pii: 689171. doi: 10.1155/2010/689171. Epub 2010 Oct 4. Review.

31.

¹³¹I-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases.

Jouneau S, Vauléon E, Caulet-Maugendre S, Polard E, Volatron AC, Meunier C, Tattevin P, Montani D, Garin E, Raoul JL, Delaval P.

Chest. 2011 Jun;139(6):1463-1469. doi: 10.1378/chest.10-1591. Epub 2010 Oct 14.

PMID:
20947651
32.

Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.

Leroux C, Vauléon E, Pracht M, Zoheir Y, Boucher E, Audrain O, Raoul JL.

Med Oncol. 2011 Dec;28 Suppl 1:S246-9. doi: 10.1007/s12032-010-9708-8. Epub 2010 Oct 9.

PMID:
20936376
33.

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.

Avril T, Saikali S, Vauleon E, Jary A, Hamlat A, De Tayrac M, Mosser J, Quillien V.

J Neuroimmunol. 2010 Aug 25;225(1-2):22-33. doi: 10.1016/j.jneuroim.2010.04.003. Epub 2010 May 20.

34.

Management of esophageal carcinoma associated with cirrhosis: a retrospective case-control analysis.

Trivin F, Boucher E, Vauléon E, Cumin I, Le Prisé E, Audrain O, Raoul JL.

J Oncol. 2009;2009:173421. doi: 10.1155/2009/173421. Epub 2009 Dec 22.

35.

Chemoradiotherapy for cancer of the esophagus: contribution of the leucovorin, 5-fluorouracil bolus, and infusion-cisplatin-radiotherapy schedule starting with two neoadjuvant chemotherapy cycles: results from a pilot study.

Tran Vuong TN, Le Prisé E, Vauléon E, Boucher E, Audrain O, Raoul JL.

Dis Esophagus. 2010 May;23(4):324-8. doi: 10.1111/j.1442-2050.2009.01016.x. Epub 2009 Oct 26.

PMID:
19863643
36.

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge.

Vauléon E, Mesbah H, Laguerre B, Gédouin D, Lefeuvre-Plesse C, Levêque J, Audrain O, Kerbrat P.

Cancer Chemother Pharmacol. 2010 May;66(1):113-20. doi: 10.1007/s00280-009-1141-3. Epub 2009 Sep 27.

PMID:
19784837
37.

Acute ischemia of the lower limb during chemotherapy for testicular cancer: A report of two cases.

Le Ho H, Vauleon E, Boucher E, Gedouin D, Kerbrat P, Raoul JL.

Acta Oncol. 2009;48(6):940-2. doi: 10.1080/02841860902759030. No abstract available.

PMID:
19235567
38.

Survival and prognostic factors in a series of adults with medulloblastomas.

Riffaud L, Saikali S, Leray E, Hamlat A, Haegelen C, Vauleon E, Lesimple T.

J Neurosurg. 2009 Sep;111(3):478-87. doi: 10.3171/2009.1.JNS081004.

PMID:
19231932
39.

Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study.

Edeline J, Raoul JL, Vauleon E, Guillygomac'h A, Boudjema K, Boucher E.

World J Gastroenterol. 2009 Feb 14;15(6):713-6.

40.

Acrokeratosis paraneoplastica (Bazex' syndrome) associated with metastatic squamous cell esophageal carcinoma.

Louvel G, Vauléon E, Boucher E, Raoul JL.

J Clin Oncol. 2008 Nov 1;26(31):5128-9. doi: 10.1200/JCO.2008.16.8641. Epub 2008 Oct 6. No abstract available.

PMID:
18838705
41.

Radiation-induced oesophageal carcinoma after breast carcinoma: a report of five cases including three successfully treated by radiochemotherapy.

Vuong NT, Boucher E, Gedouin D, Vauleon E, Le Prise E, Raoul JL.

Acta Oncol. 2007;46(8):1184-6. No abstract available.

PMID:
17851854
42.

The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.

Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, Delattre JY, Thillet J, Sanson M.

Cancer Genet Cytogenet. 2007 Jan 1;172(1):33-7.

PMID:
17175377
43.

Tonsillar metastasis revealing signet-ring cell carcinoma of the rectum.

Vauléon E, De Lajarte-Thirouard AS, Boucher E, Le Prisé E, Guihaire P, Raoul JL.

Gastroenterol Clin Biol. 2005 Jan;29(1):70-2.

44.

[Glucagonoma: a recent series of 7 cases].

Vauleon E, Egreteau J, Boucher E, Desfourneaux V, Bretagne JF, Raoul JL.

Bull Cancer. 2004 Jul-Aug;91(7-8):637-40. French.

Supplemental Content

Loading ...
Support Center